Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AbbVie's Rinvoq Bolsters Its Potential In Atopic Dermatitis

JAK1 Inhibitor ‘Clears’ Second Of Three Phase III AD Trials

Executive Summary

AbbVie's Rinvoq has performed well in the second of three Phase III studies evaluating its potential treatment for atopic dermatitis, further boosting chances the JAK1 inhibitor will become a blockbuster in that indication.

You may also be interested in...



Amgen/KK’s Atopic Dermatitis Deal Shows OX40’s Allure, But Market Still Tough

Amgen said Phase II data are planned for the EADV 2021 meeting, but KHK4083 will need a strong showing.

Oral Atopic Dermatitis Market Crowded, But Arena Sees Room

The company showed improvement on an endpoint used in several Phase III studies of JAK inhibitors, but with a potentially better safety profile.

Keeping Track: Provention Teplizumab, AZ Anifrolumab Headline Submissions; AZ Brilinta Gains Stroke Risk Reduction Claim

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel